Skip to main content

Table 2 The clinical characteristics of K. pneumoniae BSIs according to blaKPC and HM phenotype

From: Bloodstream infections caused by Klebsiella pneumoniae: prevalence of blaKPC, virulence factors and their impacts on clinical outcome

Characteristics

blaKPC+/HM+ (n = 3)

blaKPC+/HM− (n = 92)

blaKPC−/HM+ (n = 66)

blaKPC−/HM− (n = 124)

P valuec

P valued

P valuee

Demographic data

 Age (years), mean (±SD)

68.0 ± 19.2

57.4 ± 15.3

57.1 ± 13.9

56.0 ± 17.4

0.93

0.94

0.88

 Male sex

2 (66.7)

68 (73.9)

44 (66.7)

85 (68.5)

0.32

0.39

0.79

Hospitalization unit

 Medical

0

55 (59.8)

56 (84.8)

105 (84.7)

0.001

< 0.001

0.98

 ICU

3 (100)

37 (40.2)

10 (15.2)

19 (15.3)

   

Acquisition

 Nosocomial

2 (66.7)

89 (96.7)

29 (43.9)

86 (69.4)

< 0.001

< 0.001

0.001

 Community

1 (33.3)

3 (3.3)

37 (56.1)

38 (30.6)

   

Underlying diseases

 Diabetes

0

22 (23.9)

11 (16.7)

30 (24.2)

0.27

0.96

0.23

 Hematologic malignancy

1 (33.3)

7 (7.6)

3 (4.5)

20 (16.1)

0.52

0.06

0.02

 Solid tumor

1 (33.3)

11 (12.0)

21 (31.8)

34 (27.4)

0.002

0.006

0.52

 Solid organ transplantation

0

21 (22.8)

4 (6.1)

8 (6.5)

0.004

< 0.001

0.92

 Heart disease

0

16 (17.4)

8 (12.1)

11 (8.9)

0.36

0.06

0.48

 Chronic lung disease

0

10 (10.9)

10 (15.2)

8 (6.5)

0.43

0.25

0.051

 Chronic kidney disease

1 (33.3)

31 (33.7)

8 (12.1)

22 (17.7)

0.002

0.007

0.31

Origin of BSI

 Respiratory tract

2 (66.7)

29 (31.5)

7 (10.6)

11 (8.9)

0.002

0.001

0.14

 Intraabdominal

1 (33.3)

19 (20.7)

9 (13.6)

7 (5.6)

0.26

0.001

0.06

 Soft tissue

0

4 (4.3)

4 (6.1)

2 (1.6)

0.72

0.41

0.19

 Intravenous catheter

0

6 (6.5)

0

4 (3.2)

0.04

0.42

0.30

 Urinary tract

0

4 (4.3)

1 (1.5)

9 (7.3)

0.40

0.37

0.18

 Biliary tract

0

5 (5.4)

16 (24.2)

31 (25)

0.001

< 0.001

0.91

 Liver abscess

0

3 (3.3)

15 (22.7)

10 (8.1)

< 0.001

0.14

0.004

 Unknown

0

14 (15.2)

12 (18.2)

46 (37.1)

0.62

< 0.001

0.007

 Other(s)a

0

8 (8.7)

2 (3.0)

3 (2.4)

0.20

0.08

0.80

Clinical presentation

 APACHE II score, median (IQR)

25 (23.5–26.5)

23 (18–30)

14 (11–20)

15 (11–20)

< 0.001

< 0.001

0.96

 Pitt bacteremia score, median (IQR)

4 (3–4.5)

7 (2–9)

1 (1–2)

1 (0–2)

< 0.001

< 0.001

0.60

 Charlson comorbidity index, median (IQR)

2b

3 (1–4)

2 (1–3)

2 (1–4)

0.56

0.40

0.81

 Septic shock

2 (66.7)

46 (50.0)

10 (15.2)

11 (8.9)

< 0.001

< 0.001

0.19

 MODS

2 (66.7)

37 (40.2)

2 (3.0)

7 (5.6)

< 0.001

< 0.001

0.65

 Immunosuppression state

1 (33.3)

45 (48.9)

8 (12.1)

40 (32.3)

< 0.001

0.013

0.002

Therapy

 Appropriate empiric therapy

0

33 (35.9)

60 (90.9)

96 (77.4)

< 0.001

< 0.001

0.02

 Appropriate definitive therapy

0

60 (65.2)

65 (98.5)

105 (84.7)

< 0.001

0.001

0.003

14-day mortality

3 (100)

39 (42.4)

5 (7.6)

7 (5.6)

< 0.001

< 0.001

0.84

  1. Data are presented as No. (%) unless otherwise specified; boldface, indicates statistical significance (p<0.05)
  2. Abbreviations: HM hypermucoviscous, BSIs bloodstream infections, CNS central nervous system, APACHE Acute Physiology and Chronic Health Evaluation, MODS multiple organ dysfunction syndrome, SD standard deviation, IQR interquartile range
  3. aCentral nervous system infection, 9 cases; mediastinal infection, 1 cases; endocarditis, 3 cases
  4. bThe three cases had same Charlson comorbidity index
  5. cblaKPC+/HM− vs blaKPC−/HM+
  6. dblaKPC+/HM− vs blaKPC−/HM−
  7. eblaKPC−/HM+ vs blaKPC−/HM−
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us